SMN2 and proximal spinal muscular atrophy: Altogether, the direct effect of PRMT type I inhibition on SMN2 exon 7 inclusion and the potential for clinical impact of this class of molecules, prompted us to further investigate MS023 as a therapeutic agent for SMA.